Results 11 to 20 of about 19,814 (246)

Effectiveness and safety of PCSK9 inhibitor therapy in patients with familial hypercholesterolemia within a therapeutic program in Poland: Preliminary multicenter data

Cardiology Journal, 2022
BACKGROUND: In Poland, treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has become available free of charge in a therapeutic program. Assessed herein, is the efficacy and safety of alirocumab and evolocumab in patients with
Krzysztof Chlebus, Barbara Cybulska, Piotr Dobrowolski, Marzena Romanowska-Kocejko, Marta Żarczyńska-Buchowiecka, Natasza Gilis-Malinowska, Aneta Stróżyk, Justyna Borowiec-Wolna, Marcin Pajkowski, Beata Bobrowska, Renata Rajtar-Salwa, Aleksandra Kwapiszewska, Małgorzata Waluś-Miarka, Magdalena Chmara, Rafał Gałąska, Maciej Małecki, Tomasz Zdrojewski, Marcin Gruchała   +17 more
doaj   +1 more source

Young women with familial hypercholesterolemia have higher LDL-cholesterol burden than men: Novel data using repeated measurements during 12-years follow-up

Atherosclerosis Plus, 2023
Background and aims: The concentration and the duration of exposure to low-density lipoprotein cholesterol (LDL-C) (LDL-C burden) is an important determinant of risk for cardiovascular disease and thresholds has recently been estimated.
Anja K. Johansen, Martin P. Bogsrud, Jacob J. Christensen, Amanda Rundblad, Ingunn Narverud, Stine Ulven, Gisle Langslet, Kjetil Retterstøl, Kirsten B. Holven   +8 more
doaj   +1 more source

A comprehensive metabolic profiling of the metabolically healthy obesity phenotype

Lipids in Health and Disease, 2020
Background The ever-increasing prevalence of obesity constitutes a major health problem worldwide. A subgroup of obese individuals has been described as “metabolically healthy obese” (MHO).
Vibeke H. Telle-Hansen, Jacob J. Christensen, Gulla Aase Formo, Kirsten B. Holven, Stine M. Ulven   +4 more
doaj   +1 more source

The effects of cholesterol accumulation on Achilles tendon biomechanics: A cross-sectional study.

PLoS ONE, 2021
Familial hypercholesterolemia, a common genetic metabolic disorder characterized by high cholesterol levels, is involved in the development of atherosclerosis and other preventable diseases.
Kipling Squier, Alexander Scott, Michael A Hunt, Liam R Brunham, David R Wilson, Hazel Screen, Charlie M Waugh   +6 more
doaj   +1 more source

Homozygous Familial Hypercholesterolemia

Journal of Atherosclerosis and Thrombosis, 2021
Familial hypercholesterolemia (FH) is an inherited disorder with retarded clearance of plasma LDL caused by mutations of the genes involved in the LDL receptor-mediated pathway and most of them exhibit autosomal dominant inheritance. Homozygotes of FH (HoFH) may have plasma LDL-C levels, which are at least twice as high as those of heterozygous FH ...
Nohara, Atsushi, Tada, Hayato, Ogura, Masatsune, Okazaki, Sachiko, Ono, Koh, Shimano, Hitoshi, Daida, Hiroyuki, Dobashi, Kazushige, Hayashi, Toshio, Hori, Mika, Matsuki, Kota, Minamino, Tetsuo, Yokoyama, Shinji, Harada-Shiba, Mariko   +13 more
openaire   +3 more sources

Searching for new genes associated with the familial hypercholesterolemia phenotype using whole-genome sequencing and machine learning

Вавиловский журнал генетики и селекции, 2023
One of the most common congenital metabolic disorders is familial hypercholesterolemia. Familial hyper-cholesterolemia is a condition caused by a type of genetic defect leading to a decreased rate of removal of low-density lipoproteins from the ...
D. E. Ivanoshchuk, A. B. Kolker, O. V. Timoshchenko, S. E. Semaev, E. V. Shakhtshneider   +4 more
doaj   +1 more source

Hypercholesterolemia in children and adolescents: focus on the familial variant

Медицинский совет, 2021
Familial hypercholesterolemia is characterized by a significant increase in serum low-density lipoprotein cholesterol concentration, which even in the absence of other risk factors leads to the development of atherosclerotic vascular lesions beginning in
I. N. Zakharova, I. M. Osmanov, I. I. Pshenichnikova, T. M. Tvorogova, I. N. Kholodova, I. V. Berezhnaya, E. V. Skorobogatova, D. I. Kholodov, T. I. Bocharova, Yu. V. Koba   +9 more
doaj   +1 more source

Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter data

The Lancet: Digital Health, 2019
Summary: Background: Cardiovascular outcomes for people with familial hypercholesterolaemia can be improved with diagnosis and medical management. However, 90% of individuals with familial hypercholesterolaemia remain undiagnosed in the USA. We aimed to
Kelly D Myers, BS, Joshua W Knowles, MD, David Staszak, PhD, Michael D Shapiro, DO, William Howard, PhD, Mrinal Yadava, MD, David Zuzick, MBA, Latoya Williamson, MS, Nigam H Shah, PhD, Juan M Banda, PhD, Joe Leader, BS, William C Cromwell, MD, Ed Trautman, PhD, Michael F Murray, ProfMD, Seth J Baum, MD, Seth Myers, PhD, Samuel S Gidding, MD, Katherine Wilemon, BS, Daniel J Rader, ProfMD   +18 more
doaj   +1 more source

Treatment and follow-up of coronary artery disease in a child with homozygous familial hypercholesterolemia

Medicine Science, 2022
Familial hypercholesterolemia is a metabolic disease caused by a mutation in the low-density lipoprotein receptor gene. It carries early atherosclerosis and coronary artery disease risks.
Mehmet Oncul, Cemsit Karakurt, Ozlem Elkiran, Aysehan Akinci, Nevzat Erdil   +4 more
doaj   +1 more source

Familial hypercholesterolemia: Clarifications [PDF]

Cleveland Clinic Journal of Medicine, 2020
To the Editor : The article by Shah and colleagues[1][1] is an excellent review of familial hypercholesterolemia (FH) and highlights an underdiagnosed condition on which clinicians can make a significant impact.
openaire   +2 more sources